Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Oct 6 2010

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA™ (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals. CAMBIA™ is approved in the United States for the acute treatment of migraine with or without aura and was launched in the United States in June 2010.  

"Partnering with Mission allows CAMBIA™ to be introduced to approximately 15,000 physicians who focus on women's health," said James Fares, Chairman and CEO, of Nautilus Neurosciences.  "Together with Mission, and our dedicated neurology-focused sales team, CAMBIA™ is now being promoted by over 125 sales professionals in these two specialty markets.   We will now begin the process of looking to complement our partnership with Mission through the addition of a primary care partner. This will allow us to market Cambia™ to the broader general and family practice migraine market."

Terry Herring, President of Commercial Operations for Mission Pharmacal points out that "Migraine affects more than 36 million people in the United States, 75 percent of them women."  Mr. Herring adds, "At Mission, we are dedicated to bringing meaningful, differentiated products that help prescriber's meet the needs of the women in their practice.  Migraine is a unique disease in how it predominantly affects young women who in turn seek fast and convenient relief.  This important partnership with Nautilus also shows that Mission is a partner of choice in women's healthcare and urology."

According to a survey published in the Journal of the American Board of Family Medicine, many people still hope to find a better treatment for their migraines, with more than a quarter dissatisfied with their treatment and fewer than a fifth of people who suffer migraines describing themselves as "very satisfied" with their treatment.

A novel, water-soluble, buffered diclofenac potassium powder, CAMBIA™ is the only prescription non - steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine.  Engineered using Dynamic Buffering Technology™ (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research S.A., CAMBIA™ is specifically designed for fast, effective relief from the symptoms of migraine. CAMBIA™ enters the bloodstream quickly and readily achieves peak plasma concentrations, providing pain relief in fifteen minutes for some patients.